Aqr Capital Management LLC Intercept Pharmaceuticals, Inc. Transaction History

Aqr Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$24.48 - $42.47 $333,735 - $578,993	-13,633 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$39.09 - $53.44 $240,442 - $328,709	-6,151 Reduced 31.09%	13,633 $565,000
Q2 2020 Aug 17, 2020	BUY	$46.7 - $92.04 $66,080 - $130,236	1,415 Added 7.7%	19,784 $948,000
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $95,878 - $235,342	-1,983 Reduced 9.74%	18,369 $1.16 Million
Q4 2019 Feb 14, 2020	SELL	$57.36 - $124.1 $241,944 - $523,453	-4,218 Reduced 17.17%	20,352 $2.52 Million
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $465,646 - $638,369	-7,934 Reduced 24.41%	24,570 $1.63 Million
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $233 - $362	-3 Reduced 0.01%	32,504 $2.59 Million
Q1 2019 May 14, 2019	BUY	$91.83 - $120.68 $19,376 - $25,463	211 Added 0.65%	32,507 $3.64 Million
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $893,846 - $1.32 Million	10,419 Added 47.63%	32,296 $3.26 Million
Q3 2018 Nov 15, 2018	BUY	$88.49 - $127.55 $1.94 Million - $2.79 Million	21,877 New	21,877 $2.76 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.